Teng, Y K Onno <br/><br/>
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.  [electronic resource] 

 -  BMJ open  03 2019 
 - e025687 p.  digital 
<br/><br/> Publication Type: Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2044-6055 
<br/><br/><label>Standard No.: </label>10.1136/bmjopen-2018-025687  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Clinical Trials, Phase III as Topic<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Immunosuppressive Agents--administration & dosage<br/>Injections, Subcutaneous<br/>Lupus Erythematosus, Systemic--drug therapy<br/>Male<br/>Middle Aged<br/>Multicenter Studies as Topic<br/>Prednisone--administration & dosage<br/>Randomized Controlled Trials as Topic<br/>Rituximab--administration & dosage<br/>Severity of Illness Index<br/>Treatment Outcome